News & Updates
Filter by Specialty:
Ixekizumab effective for difficult-to-treat psoriatic arthritis
The monoclonal antibody ixekizumab improved the signs and symptoms of psoriatic arthritis (PsA) in PsA patients with inadequate response to one or two tumour necrosis factor inhibitors (TNFis), suggests results from a post hoc subanalysis of the SPIRIT-P2 trial.
Ixekizumab effective for difficult-to-treat psoriatic arthritis
08 Dec 2021
AECOPD outcomes unaltered with short-course nonmacrolide therapy
Short-course nonmacrolide therapy in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) appears to have no significant effect on outcomes including mortality, progression to ventilation, readmission rate, or prevalence of adverse drug events, a study has shown.
AECOPD outcomes unaltered with short-course nonmacrolide therapy
08 Dec 2021
Cholinesterase inhibitors show promise for treating gait disturbance in PD
Treatment with cholinesterase inhibitors in patients with Parkinson’s disease (PD) leads to significant improvements in gait variability, with trending benefits for gait speed and fall prevention, according to the results of a meta-analysis.
Cholinesterase inhibitors show promise for treating gait disturbance in PD
07 Dec 2021
Birth control pills pose inflammatory bowel disease risk
The use of combined oral contraceptive pills (COCPs) appears to confer some risk of inflammatory bowel disease, which increases accordingly with duration of COCP exposure, as shown in a study.
